Does turkey tail as an adjuvant therapy improve the quality of life of canine lymphoma patients?

PICO question In canine lymphoma, does the supplement of turkey tail (Trametes versicolor) as an adjuvant therapy lead to a better quality of life than those that do not?   Clinical bottom line Category of research question Treatment The number and type of study designs reviewed One prospective case series was critically appraised Strength of evidence Very weak Outcomes reported The case series assessed appetite and activity level of the canine lymphoma patients. They also measured gastrointestinal toxicity and the incidence of neutropenia Conclusion This prospective case series is insufficient to support the use of turkey tail to enhance the quality of life of canine lymphoma patients. A controlled study is required to evaluate whether the use of turkey tail supplement is useful   How to apply this evidence in practice The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.